Changes in Fatigue, Psychological Distress, and Quality of Life After Chemotherapy in Women with Breast Cancer A Prospective Study
Changes in Fatigue, Psychological Distress, and Quality of Life After Chemotherapy in Women with Breast Cancer A Prospective Study
复制标题
乳腺癌患者化疗后疲劳、心理困扰和生活质量的变化:一项前瞻性研究
DOI:
10.1097/ncc.0000000000000689
复制
发表时间:
2020-01-01
期刊:
影响因子:
2.6
通讯作者:
Cho, Jung-Ran
中科院分区:
文献类型:
--
作者:
Oh, Pok-Ja;Cho, Jung-Ran
Background Chemotherapy leads to various symptoms and psychological distress, which contribute to a significant decrease in the quality of life of the patients. Objectives The aim of this study was to identify changes and interrelationships in the fatigue-depression-anxiety symptom cluster and quality of life during the cancer care trajectory in women with breast cancer. Methods Fifty women participated in the study and completed questionnaires at 3 different times: prechemotherapy, postchemotherapy, and 6 months after the completion of chemotherapy. The assessment tools were the Functional Assessment of Cancer Therapy-Fatigue Scale, Hospital Anxiety and Depression Scale, and Functional Assessment of Cancer Therapy-Breast Cancer version 4 Scale. Data were analyzed using descriptive and repeated-measures analysis of variance statistics. Results A significant increase in fatigue (F = 41.95, P < .001) and psychological distress (F = 26.55, P < .001) from prechemotherapy to postchemotherapy was noted. Improvement was observed 6 months after the completion of chemotherapy. A positive or negative change in fatigue was associated with the same in psychological distress. Quality of life (F = 65.22, P < .001) also showed similar change patterns as observed with fatigue and psychological distress. Fatigue had a greater impact on quality of life at postchemotherapy, but psychological distress had a greater impact at prechemotherapy and at the 6-month follow-up. Conclusion These results suggest that chemotherapy is highly associated with the fatigue-depression-anxiety symptom cluster and quality of life in women with breast cancer.